Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Lung cancer; Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 Apr 2017 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
- 26 Sep 2016 Status changed from not yet recruiting to recruiting.
- 01 Aug 2016 New trial record